MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
112.00
+0.05
+0.04%
After Hours: 112.00 0 0.00% 19:30 09/28 EDT
OPEN
111.95
PREV CLOSE
111.95
HIGH
113.60
LOW
110.51
VOLUME
723.65K
TURNOVER
--
52 WEEK HIGH
130.05
52 WEEK LOW
54.09
MARKET CAP
9.31B
P/E (TTM)
-34.5572
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
TipRanks · 12h ago
Weekly Report: what happened at KYMR last week (0921-0925)?
Weekly Report · 13h ago
Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)
TipRanks · 5d ago
Kymera Therapeutics Is Maintained at Buy by Stifel
Dow Jones · 6d ago
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Benzinga · 6d ago
Kymera Therapeutics price target raised to $152 from $132 at Stifel
TipRanks · 6d ago
Weekly Report: what happened at KYMR last week (0914-0918)?
Weekly Report · 09/21 09:49
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.